Apremile 30 Tablet contains Apremilast (30 mg), a selective phosphodiesterase 4 (PDE4) inhibitor used in the management of moderate to severe plaque psoriasis and psoriatic arthritis. It works by reducing the activity of inflammatory mediators that trigger skin lesions and joint pain, leading to visible improvement in both skin texture and flexibility.
By targeting the underlying inflammatory pathways, Apremilast 30 mg helps in controlling scaling, redness, swelling, and stiffness without the immunosuppressive side effects of conventional systemic therapies.
This formulation is part of the Dermatology and Rheumatology segment, making it a valuable addition for PCD pharma franchise partners, third-party manufacturing, and export businesses. With its rising prescription trend in dermatology and orthopedic clinics, Apremile 30 Tablet ensures consistent B2B growth potential and strong market demand across India.
Common side effects may include nausea, diarrhea, headache, loss of appetite, or weight loss. Rarely, mood changes or depression may occur. Notify your doctor immediately if you experience persistent diarrhea, sudden mood changes, or unexplained weight loss.
Apremile 30 Tablet is indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis in adults. It helps relieve symptoms such as scaling, itching, and joint pain, improving skin health and mobility.
Take Apremile 30 Tablet exactly as prescribed, with or without food. Do not stop the medication abruptly without consulting your healthcare provider. Regular monitoring of body weight and mental health is advised during therapy. Inform your doctor if you are pregnant, breastfeeding, or have kidney or liver impairment.
Store Apremile 30 Tablet in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep the medicine out of reach of children.